Sandoz: Additional Delay Of First Biosimilar's Marketing Would Harm Patients

Sandoz pushed back against Amgen's “emergency motion” to block the biosimilar sponsor from bringing its filgrastim product Zarxio to market on Sept. 3, saying in court documents Monday (Aug. 31) that a further marketing delay would cause cancer patients significant harm. The case is being closely watched because Zarxio is the first biosimilar approved by FDA. Amgen filed an emergency motion for an injunction last week that would prevent Sandoz from marketing, selling, offering for sale or importing to the...